Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - OtherShort-Term Debt repayments
Ratios

Abvc Biopharma (ABVC) Accumulated Depreciation & Amortization (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Depreciation & Amortization fell 68.5% year-over-year to $3.4 million, compared with a TTM value of $3.4 million through Sep 2025, down 68.5%, and an annual FY2024 reading of $3.3 million, up 182.21% over the prior year.
  • Accumulated Depreciation & Amortization was $3.4 million for Q3 2025 at Abvc Biopharma, up from $3.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $10.7 million in Q3 2024 and bottomed at -$4.1 million in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.1 million, with a median of $7228.0 recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization crashed 17180.38% in 2023, then soared 143950.84% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $11993.0 in 2021, then skyrocketed by 98.44% to $23799.0 in 2022, then plummeted by 17180.38% to -$4.1 million in 2023, then surged by 182.21% to $3.3 million in 2024, then grew by 1.28% to $3.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ABVC at $3.4 million in Q3 2025, $3.3 million in Q4 2024, and $10.7 million in Q3 2024.